Loading clinical trials...
Loading clinical trials...
An Open-label, Single Dose, Three Sequence Study in Healthy Adult Volunteers to Evaluate the Pharmacokinetics, Safety and Tolerability of RV521 Administered as the Drug in Capsule Formulation in the Fed State and the Dry Powder Blend Formulation Dispersed in Water in the Fed and Fasted States
The main aims of the study are to assess the pharmacokinetics and safety of single doses of RV521 administered as two different formulations
Age
18 - 45 years
Sex
ALL
Healthy Volunteers
Yes
Richmond Pharmacology Ltd
London, United Kingdom
Start Date
August 13, 2019
Primary Completion Date
September 2, 2019
Completion Date
September 9, 2019
Last Updated
June 7, 2024
9
ACTUAL participants
RV521
DRUG
Lead Sponsor
Pfizer
NCT07220109
NCT07092865
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07239583